Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigil (FANG) vaccine in high-risk ovarian cancer
NCT01309230Phase 2Completed
- Sponsor
- Gradalis, Inc.
- Start
- Mar 2011
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA), Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of gemogenovatucel-T in ovarian cancer, sponsored by Gradalis, Inc.. Started Mar 2011; status: completed.
02
Drugs
gemogenovatucel-T
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01309230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01309230.